Amabile G, Serradimigni A
C.H.U. de la Timone, Service de Cardiologie, Marseille, France.
Eur Heart J. 1987 Dec;8 Suppl M:65-9. doi: 10.1093/eurheartj/8.suppl_m.65.
Beta blockers are often considered to be less effective for blood pressure control in elderly patients with essential hypertension than calcium antagonists. We therefore compared the efficacy and tolerability of the new beta blocker bisoprolol with those of nifedipine. Fifty-nine patients over 60 years of age with essential hypertension (supine diastolic blood pressure, DBP: 95-115 mmHg) took part in a randomized double-blind study. After 14 days on placebo the patients received either 10 mg bisoprolol o.d. or 20 mg nifedipine SR b.i.d. for 4 weeks. The doses were doubled in patients whose DBP remained greater than 90 mmHg, for a further 4 week period. Blood pressure was measured about 24 hours after bisoprolol and about 12 hours after nifedipine administration. Fifty-six patients were available for efficacy analysis. After 4 weeks there was a distinct decrease of SBP and DBP in both groups (bisoprolol: -22 +/- 16; -15 +/- 9 mmHg; nifedipine: -24 +/- 17; -17 +/- 7 mmHg) with no significant difference between the treatments. DBP was normalized in 22/28 (79%) patients on bisoprolol and in 24/28 (86%) patients on nifedipine (bisoprolol vs nifedipine: NS). There were 7/29 bisoprolol and 14/30 nifedipine patients who experienced at least one side-effect. Overall the tolerability of bisoprolol was considered to be better than that of nifedipine (P = 0.043). In conclusion, bisoprolol 10-20 mg o.d. proved to be as equally effective as nifedipine SR 20-40 mg b.i.d. for the treatment of essential hypertension in the elderly.
在老年原发性高血压患者中,β受体阻滞剂对血压控制的效果通常被认为不如钙拮抗剂。因此,我们比较了新型β受体阻滞剂比索洛尔与硝苯地平的疗效和耐受性。59例60岁以上的原发性高血压患者(仰卧位舒张压,DBP:95 - 115 mmHg)参与了一项随机双盲研究。在服用安慰剂14天后,患者接受每日一次10 mg比索洛尔或每日两次20 mg硝苯地平缓释片治疗4周。DBP仍大于90 mmHg的患者,剂量加倍,再治疗4周。在服用比索洛尔约24小时后和服用硝苯地平约12小时后测量血压。56例患者可进行疗效分析。4周后,两组的收缩压和舒张压均明显下降(比索洛尔:-22±16;-15±9 mmHg;硝苯地平:-24±17;-17±7 mmHg),治疗之间无显著差异。服用比索洛尔的22/28(79%)患者和服用硝苯地平的24/28(86%)患者DBP恢复正常(比索洛尔与硝苯地平:无显著性差异)。服用比索洛尔的患者中有7/29和服用硝苯地平的患者中有14/30经历了至少一种副作用。总体而言,比索洛尔的耐受性被认为优于硝苯地平(P = 0.043)。总之,每日一次服用10 - 20 mg比索洛尔在治疗老年原发性高血压方面被证明与每日两次服用20 - 40 mg硝苯地平缓释片同样有效。